P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS

P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS

Introduction and Objectives: Tenofovir Alafenamide (TAF) is a preferred treatment in the most recent EASL and AASLD HBV Guidelines, especially in patients with risk factors for TDF-associated renal and bone effects. In 2 identically-designed double-blind (DB), randomized (2:1), Phase 3 studies (HBeA...

Full description

Bibliographic Details
Main Authors: Wai Kay Seto, Ting-Tsung Chang, Abhijit Chowdhry, Chi-Yi Chen, Mustafa Kemal Celen, Xiaoli Ma, Mang Ma, Ajay Duseja, Ki Tae Yoon, Wan Cheng Chow, Leland Yee, Gregor Weber, Ms Jin Youn, John F. Flaherty, Anuj Gaggar, Bing Gao, Gregory Camus, Eric Bassetti, Jae Seok Hwang, Tetshuro Inokuma, Young- Suk Lin, Edward J. Gane
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Annals of Hepatology
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268123000091

Similar Items

Similar Items